Single-Session High-Dose Hyaluronidase for Managing Periorbital Hyaluronic Acid Filler Complications.

Aesthetic plastic surgery 2026 Vol.50(4) p. 1596-1602

Chen J, Zhang F, Li C, Wang Y, Li Q, Weng X, Peng G

관련 도메인

Abstract

[BACKGROUND] Periorbital complications from hyaluronic acid (HA) fillers are common due to the region's unique anatomy. Hyaluronidase is widely used for management, but dosing remains empirical with no standardized protocol. This study aimed to assess the safety and efficacy of a high-dose, single-session hyaluronidase approach for treating such complications.

[METHODS] A retrospective study was conducted on 54 patients presenting with periorbital HA-related complications between August 2020 and May 2024. Four main types of complications were identified: persistent edema, tear trough bulging, under-correction, and subcutaneous nodules. The average interval from the first HA injection to presentation was 25.8 months (range 1.5-72 months). Injection points were determined through visual inspection and palpation, marked at the most prominent areas, and spaced approximately 7-10 mm apart. A vertical bolus injection technique was used to administer 30-90 IU (0.1-0.3 mL) of hyaluronidase per point, totaling 150-600 IU per lower eyelid.

[RESULTS] The mean follow-up was 52.9 days (range 14-474 days). All patients responded successfully to one session of high-dose hyaluronidase. The mean dose per lower eyelid was 350.3 IU. No cases required retreatment. Nineteen patients (35.2%) achieved satisfactory outcomes without further intervention, while the remaining 35 (64.8%) underwent subsequent lower eyelid blepharoplasty.

[CONCLUSION] High-dose, single-session hyaluronidase injection is a safe, effective, and efficient approach for treating a broad range of HA-related periorbital complications, even in complex cases involving multiple previous treatments or long filler retention time.

[LEVEL OF EVIDENCE IV] This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
재료 ha 히알루론산 dict 4
해부 lower eyelid 눈꺼풀 dict 3
재료 hyaluronic acid 히알루론산 dict 2
시술 blepharoplasty 안검성형술 dict 1
시술 hyaluronic acid filler 필러 주입술 dict 1
시술 filler 필러 주입술 dict 1
해부 periorbital scispacy 1
해부 tear scispacy 1
해부 subcutaneous nodules. scispacy 1
해부 eyelid scispacy 1
해부 subcutaneous 피하조직 dict 1
합병증 edema scispacy 1
합병증 eyelid scispacy 1
약물 high-dose scispacy 1
약물 [BACKGROUND] Periorbital complications scispacy 1
약물 high-dose hyaluronidase scispacy 1
질환 edema C0013604
Edema
scispacy 1
질환 under-correction scispacy 1
질환 Periorbital Hyaluronic Acid scispacy 1
기타 Hyaluronidase scispacy 1
기타 patients scispacy 1

MeSH Terms

Humans; Hyaluronoglucosaminidase; Retrospective Studies; Hyaluronic Acid; Female; Dermal Fillers; Middle Aged; Adult; Male; Treatment Outcome; Cosmetic Techniques; Aged; Follow-Up Studies; Skin Aging; Eyelids; Dose-Response Relationship, Drug

📑 인용 관계

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문